
MDxHealth SA (MDXH) Stock Forecast & Price Target
MDxHealth SA (MDXH) Analyst Ratings
Bulls say
MDxHealth is a company operating in the healthcare sector, providing molecular diagnostic information for personalized cancer treatment. Despite announcing a lower revenue forecast for 2026, the company is still recommended as a buy with a lowered price target due to its success in acquiring new tests and increased productivity. With a track record of successful acquisitions and strong revenue growth, MDxHealth is positioned for continued success in the urology market.
Bears say
MDxHealth is facing multiple challenges, such as a weaker-than-expected Q1'26 performance, a potential recoupment payment of $10 million related to its Resolve UTI test, and the decision to discontinue the test and shut down the TX lab, leading to a reduction in revenue estimates for 2026 and 2027. Additionally, while the company has acquired the ExoDx test, generating $20 million in annual revenue, it will take time to contribute to the company's bottom line. The company's tight cash flow and high debt levels also pose a risk, as does its dependence on government funding for research and development. Given these issues, the stock has seen a ~35% decline and a lowered price target from $7 to $4.
This aggregate rating is based on analysts' research of MDxHealth SA and is not a guaranteed prediction by Public.com or investment advice.
MDxHealth SA (MDXH) Analyst Forecast & Price Prediction
Start investing in MDxHealth SA (MDXH)
Order type
Buy in
Order amount
Est. shares
0 shares